Introduction
CD34 antigen has been widely used as a marker of stem/progenitor cells. 1 Therefore, positive selection of CD34 þ peripheral blood stem cells (PBSCs) is employed for both allogeneic and autologous hematopoietic stem cell (HSC) transplantation. 2, 3 So far, two immunomagnetic beads systems, the Isolex 300 (300i) [4] [5] [6] [7] [8] [9] [10] [11] [12] and the CliniMACS, [13] [14] [15] [16] [17] have been widely used in the clinical field. Most studies have shown that rapid and stable neutrophil and platelet engraftment occurs in patients who receive at least 2 Â 10 6 CD34 þ cells/kg. 5, 6, [9] [10] [11] [13] [14] [15] [16] However, previous studies have only assessed the efficiency of CD34 þ cell recovery, CD34
þ cell purity, depletion of CD3 þ T lymphocytes, and tumor cell purging. Therefore, it is necessary to more precisely elucidate the functional property of the CD34 þ cells selected by these immunomagnetic beads systems, since the detailed properties of selected CD34 þ hematopoietic stem/progenitor, especially their long-term bone marrow (BM) repopulating activity, have not yet been fully elucidated.
Definitive evidence that selected CD34
þ cells retain HSC activity will only be obtained by assessing the lifelong outcome of clinical CD34 þ cell transplantation. In this study, we performed a detailed investigation of the stem/progenitor cell activity of CD34 þ cells selected by two immunomagnetic beads systems, the laboratory scale Isolex 50 and MiniMACS, using various in vitro culture systems as well as an in vivo severe combined immunodeficiency (SCID)-repopulating cell (SRC) assay. 18 The results were compared with those for CD34
þ cells enriched by the StemSep device (a negative selection method). Our data clearly demonstrated that CD34 þ cells selected by the MiniMACS system had several advantages over cells selected by the Isolex 50 system.
Materials and methods

Recombinant factors
Purified bacterially derived recombinant human (rh) interleukin-3 (IL-3), granulocyte/macrophage (GM)-colony-stimulating factor (CSF), granulocyte (G)-CSF, stem cell factor (SCF), and purified Chinese hamster ovary cell-derived rh erythropoietin (Epo) were generous gifts from Kirin Brewery Co., Ltd (Tokyo, Japan). Purified rh thrombopoietin (TPO) was prepared by the TPO production group (Kirin Brewery) and was supplied for this study.
Cell preparation
After informed consent was obtained, PB mononuclear (MN) cells were collected by leukapheresis using a Fenwall CS-3000 Plus (Fenwall Laboratories, Inc., Deerfild, IL, USA) from nine patients with non-Hodgkin's lymphoma (NHLs) and two healthy adult PBSC donors. All patients were in their first complete remission after standard induction chemotherapy. A profile of the patients and the samples obtained is presented in Table 1 . The details of the methods used for cell collection have been reported elsewhere. 19, 20 Briefly, hematopoietic stem/progenitor cells were mobilized into the PB of patients with NHL by a combination of conditioning chemotherapy regimens, including CHOP, high-dose (HD) etoposide, and HD cytosine arabinoside with G-CSF. The healthy PBSC donors received G-CSF treatment (5 mg/kg/day) for 5 days, after which leukapheresis was preformed on days 6 and 7. PBSC collection was begun within 3 days of the white blood cell count rising above 1000/ml in the NHL patients. Cells were centrifuged at 150 g for 15 min in the collection bag and buffy-coat cells were transferred to the second bag. These cells were diluted with an equal volume of RPMI 1640 medium (BioWhittaker, Walkersville, MD, USA). PBMN cell suspensions were gently mixed with an equal volume of a cryoprotective solution consisting of 12% hydroxyethyl starch, 10% dimethyl sulfoxide, and 8% human serum albumin, and were subsequently frozen in cryopreservation bags at À801C overnight in an electrical freezer without rate control, followed by storage in liquid nitrogen, as reported elsewhere. 19, 20 Prior to freezing, a portion of each patient's cell specimen was removed and low-density MN cells were separated by Ficoll-Paque (Pharmacia, Piscataway, NJ, USA) density-gradient centrifugation at 400 g for 30 min for use in the present study. These cells were washed twice with a-medium (Dainippon Pharmaceutical Co., Ltd, Australia) containing 10% fetal calf serum (FCS, Hyclone Laboratories, Logan, UT, USA), and nonadherent cells were recovered after allowing adherence to plastic dishes for 1 h. The MN nonadherent (MNNA) cell fraction was used for selection of CD34 þ cells by two different immunomagnetic beads systems. In some experiments, frozen MN cells from four patients with NHL and two healthy donors were thawed rapidly and used for positive as well as negative selection of CD34 þ cells. The PB MNNA cells obtained from the NHL patients and healthy PBSC donors had an average CD34 þ cell content of 8.176.0% (n ¼ 9) and 2.271.3% (n ¼ 2), respectively, on flow cytometric analysis (Tables 1 and 3) .
Immunomagnetic isolation/enrichment of CD34 þ cells
The above-mentioned samples were washed twice with Dulbecco's phosphate-buffered saline (D-PBS À ) containing 1% human albumin and 0.6% ACD-A. For positive selection of CD34 þ cells, samples were divided into two equal parts, and then further separated by two different laboratory immunomagnetic beads systems, that is, the MiniMACS system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and the Isolex 50 system (Nexell Therapeutics, Inc., Irvine, CA, USA), according to the respective manufacturer's instructions. Some samples obtained from two patients with NHL (Cases 4 and 9 in Table 1 ) and two healthy donors (Table 3) were divided into three equal parts and then separated by three different laboratory immunomagnetic beads systems, that is, the MiniMACS, the Isolex 50, and the StemSep device (a negative selection method) (StemCell Technologies, Vancouver, BC, Canada).
For Isolex 50 selection, MNNA cells were incubated at room temperature for 30 min with a mouse anti-human CD34 monoclonal antibody (mAb) (9C5, Nexell Therapeutics). The mAb-coated cells were washed twice with working buffer and mixed with sheep anti-mouse IgG-coated paramagnetic beads (Dynal, Oslo, Norway). Next, the cellbead suspension was incubated at room temperature for 30 min. Then mAb-coated CD34 þ cells binding to the magnetic beads were immobilized by applying the Dynal MPC-1. The nontarget cells were removed from the cell-bead suspension and the rosetted cells were washed twice with buffer. After this wash, the CD34 þ cells were released from the magnetic beads by adding a releasing peptide (PR34 þ ) and incubating for 30 min at room temperature. The released beads were immobilized by applying the Dynal MPC-1, and the CD34 þ cells were collected and washed twice with a-medium.
For MiniMACS separation, after the treatment with FcRblocking reagent, MNNA cells were incubated with CD34 Microbeads (Miltenyi Biotec) at 6-121C for 30 min. Then the magnetically labeled target cells were enriched on positive selection columns inside the magnetic field of the MiniMACS. Nontarget cells passed through the columns and were recovered in the elution buffer. After removing the columns from the MiniMACS separator, the retained CD34 þ cells were eluted with buffer using the plunger and the recovered CD34 þ cells were washed twice with a-medium.
For negative selection of CD34 þ cells using the StemSep device, lineage-positive cells were removed with nine lineage (CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A (GPA)) mAbs, as reported elsewhere. 21 Briefly, MNNA cells were incubated on ice for 15 min with the abovementioned nine tetrameric mAbs (StemCell Technologies). Then 20-nm magnetic colloidal iron-dextran particles were added and incubation was continued for a further 15 min, after which the cells were processed through the StemSep device for depletion of target cells. Following the negative depletion procedure, lineage-negative (Lin À ) cells were recovered in the eluted fraction. These PBSC-derived Lin À cells had approximately 90% content of CD34 þ cells by flow cytometric analysis (Table 3) .
In each experiment, 0.7 Â 10 7 -1 Â 10 8 cells were used (Tables  1 and 3) , and cell viability after each process of these procedures was confirmed to be greater than 98% by trypan blue dye exclusion. þ cell fractions, and the CD34-negative (CD34 À ) cell fractions was analyzed by flow cytometry after staining with a phycoerythrin (PE)-conjugated anti-human CD34 mAb (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA). Treatment with 7-amino-actinomycin D (7AAD) (Calbiochem-Novabiochem, Nottingham, UK) was used to gate out dead cells (7AAD bright), as reported elsewhere. 22 All flow cytometric analyses were carried out on a FACSCalibur (Becton Dickinson), as described elsewhere. 21, 23 Data acquisition were performed using CELLQuest software (Becton Dickinson) and at least 2 Â 10 4 events were analyzed for each sample.
Clonal cell culture
Colony formation by 1 Â 10 4 MNNA cells, 1 Â 10 4 CD34-depleted (CD34 À ) cells, or 500 CD34 þ cells was assessed in 35 mm Lux suspension culture dishes (no. 171099, Nunc Inc., Naperville, IL, USA) using serum-containing methylcellulose culture medium and various combinations of CSFs, as reported previously. 21, [23] [24] [25] The final concentration of each CSF was as follows: IL-3, 10 ng/ml; GM-CSF, 10 ng/ml; G-CSF, 20 ng/ml; Epo, 2 U/ml; and SCF, 20 ng/ml. These concentrations supported maximal total colony formation in preliminary titration experiments (data not shown). In the case of megakaryocyte colony formation, 2 Â 10 4 MNNA cells, 2 Â 10 4 CD34 À cells, or 1000 CD34 þ cells were plated in culture dishes containing 10% platelet-poor plasma and 100 ng/ml TPO, as reported elsewhere. 21, 26 The dishes were incubated at 371C in a fully humidified atmosphere flushed with a combination of 5% CO 2 , 5% O 2 , and 90% N 2 . All colonies were counted under an inverted microscope on days 12-14 of incubation. The typical morphologic appearance, reported elsewhere, 21, [23] [24] [25] [26] was used to identify GM colonies (CFU-GM), erythroid burst-forming units (BFU-E), erythrocyte-containing mixed colonies (CFUMix), and megakaryocyte colonies (CFU-Meg).
Cobblestone area-forming cell assay
The MS-5 murine stromal cell line 27 was maintained in amedium supplemented with 10% FCS, as reported elsewhere. 28 For coculture with 5 Â 10 3 CD34 þ or 5 Â 10 4 MNNA cells, unirradiated MS-5 feeder cells (5 Â 10 3 /well) were pre-established in gelatin-coated four-well plates (no. 176740, Nunc Inc.). Coculture was initiated in stromal medium, which contained a-medium, 10% FCS, 10% horse serum (BioWhittaker), and 5 Â 10 À5 mol/l 2-ME, and a half-medium change was carried out weekly. After 5 weeks of incubation, phase-dark hematopoietic clones of at least five cells beneath the stromal cell layer were identified under an inverted microscope as cobblestone area-forming cells (CAFCs), as reported previously. 29 
SRC assay
NOD/Shi-scid/scid (NOD/SCID) mice 5-week-old were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan). This animal experiment was approved by the Animal Care Committee of Kyoto Prefectural University of Medicine. All mice were handled under sterile conditions and maintained in germ-free isolators located in the Central Laboratory Animal Facility of Kyoto Prefectural University of Medicine. Xenotransplantation was performed by a modification of the method reported previously. 18, 30, 31 Briefly, positively or negatively purified CD34 þ cells (5 Â 10 5 cells) were transplanted by tail vein injection into sublethally irradiated 8-to 12-week-old NOD/SCID mice (250 cGy using 137 Cs girradiation). In order to reduce natural killer cell activity, the recipient mice were injected intraperitoneally with 400 ml of PBS À containing 20 ml of anti-asialo GM1 antiserum (Wako, Osaka, Japan) just prior to transplantation. Mice were killed at 12 weeks after transplantation, and the BM cells from the bilateral femurs, tibiae, and humeri of each mouse were flushed into a-medium. Cells were filtered through a cell strainer (no. 2350, Becton Dickinson) and were then processed for flow cytometric analysis as described below.
Repopulation of murine BM by human hematopoietic cells was determined by detecting cells showing positive staining by PC5-conjugated anti-human CD45 (Immunotech SA, Marseille, Cedex, France). Cells were also stained with PE-conjugated antihuman CD34 (Becton Dickinson), and with mAbs for lineagespecific antigens, including anti-human CD3 conjugated with fluorescein isothiocyanate (FITC) (Immunotech), CD19-FITC (Immunotech), CD33-FITC (eBioscience, San Diego, CA, USA), CD14-FITC (Becton Dickinson), CD41-FITC (Immunotech), and GPA-FITC (Dako Japan Co., Ltd, Kyoto, Japan) to detect specific subsets of human hematopoietic cells. Briefly, BM cells were suspended in PBS À containing 2% FCS after lysis of red blood cells with 6% ammonium chloride. Cells were then incubated with human IgG followed by staining with the abovementioned mAbs. Next, the hematopoietic cell subsets were quantified by gating on human CD45 þ cells and then assessing the extent of staining by anti-human CD34 and the lineagespecific mAbs, except that GPA was assessed using whole BM cells without lysis of red blood cells. All flow cytometric analyses were carried out on a FACSCalibur (Becton Dickinson), as described elsewhere.
21,23,31
Statistical analysis
The significance of differences was determined using the MannWhitney U-test.
Results
Recovery of CD34
þ cells and total CFCs in the CD34 
Next, we compared the recovery of CD34 þ cells and total CFCs from each pair of patient samples (Figure 1a and b) . The recovery rate was consistently higher when samples were separated by the MiniMACS than when the corresponding samples were separated by the Isolex 50 irrespective of whether the cells were fresh or frozen.
Purity of enriched cells
The purity of CD34 þ cells separated by the two systems was determined by flow cytometry. As presented in Figure 2 , the purity was above 80% for eight out of nine samples after selection by both systems. The median purity was 88.6% for the MiniMACS and 90.6% for the Isolex 50, showing no significant difference.
Residual CD34
þ cells and total CFCs in the CD34 À cell fraction Next, we examined the CD34 þ cells and total CFCs remaining in the CD34 À cell fraction after separation by each method. As shown in Figure 3 , a large number of CD34 þ cells and total CFCs were recovered from the CD34 À cell fraction after separation by either system. The residual cell rates were consistently higher in samples separated by the Isolex 50 than The recovery rate (%) for total CFCs was calculated as follows: absolute number of total CFCs in immunomagnetically separated CD34 + cell fraction/absolute number of total CFCs in the MNNA cell fraction Â 100. After Isolex 50 separation, 15.1-68.4% (median, 41.7%) of the CD34 À cell fraction was composed of CD34 þ cells, which was greater than the percentage (36.1%) recovered in the CD34 þ cell fraction (Figure 3a) . In contrast, CD34 þ cells accounted for 0.8-57.1% (median, 9.5%) of the CD34 À cell fraction obtained using the MiniMACS and the difference between the two methods was significant (Po0.01). The median percentage of total CFCs in the CD34 À cell fractions selected by the MiniMACS and Isolex 50 was 5.0 and 18.9%, respectively (Figure 3b ), but the difference between the two methods was not significant (P ¼ 0.07). These results demonstrated that a large number of CD34 þ cells and total CFCs escaped into the CD34 À cell fraction when either system was used.
Colony-forming ability of isolated CD34 þ cells
We subsequently compared the colony-forming ability of the isolated CD34 þ cells and the results are shown in Table 2 . 
Quantitation of CAFCs in isolated CD34
þ cells
Next, we measured the number of CAFCs, which represent a class of immature progenitor cells, 29 generated by 5 Â 10 3 CD34 þ cells that had been separated using each of the two systems. Representative data from six independent experiments using six different samples are shown in Figure 4 . The median number of CAFCs was 2 for the Isolex 50 and 85.5 for the MiniMACS. These results clearly demonstrated that CD34 þ cells selected by the MiniMACS system had significantly higher CAFC activity than those selected by the Isolex 50 (Po0.01).
Hematopoietic progenitor cell activity of positively or negatively selected CD34 þ cells from healthy donors
To further evaluate the hematopoietic progenitor cell (HPC) activity of CD34 þ cells selected by the Isolex 50 or the MiniMACS, we performed a comparison with CD34 þ cells enriched by the StemSep (a negative selection device) ( Table 3) . In these experiments, we used PBSCs obtained from two healthy donors in order to exclude any effect of conditioning chemotherapy on HPC/HSC activity. Both the purity and the recovery rate of CD34 þ cells were comparable to those obtained from patients with NHL (see Figures 1a and 2) . The total number of CFCs or CAFCs generated by 500 or 5 Â 10 (Figure 5a ) and two from healthy donors (Figure 5b) ). SRC activity was detected in all 38 mice. As shown in Figure 5a , the percentage of human CD45 þ cells among murine BM cells ranged from 0.6 to 44.0% (median, 1.8%) for the Isolex 50, from 1.7 to 53.2% (median, 16.7%) for the MiniMACS, and from 2.1 to 30.3% (median, 13.6%) for the StemSep. The CD45 þ cell repopulation rate achieved with SRCs derived from CD34 þ cells separated by the MiniMACS was significantly higher than that obtained using cells separated by the Isolex 50 (Po0.05), while the CD45 þ cell repopulation rate after transplantation of CD34 þ cells separated by the StemSep was comparable with that obtained using the MiniMACS. The pattern of CD45 þ cell repopulation achieved with SRC derived from CD34 þ cells separated by these methods was almost identical whether the source was NHL patients (Figure 5a þ cells selected by the Isolex 50 system as well as the StemSep device also achieved multilineage reconstitution of the BM (data not shown).
Discussion
The present findings concerning CD34 þ cell recovery and purity were comparable with our previous experience using the Isolex 300 32 and with other reports on clinical-grade devices, including the CliniMACS and the Isolex 300 (300i). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In general, approximately 80% of CD34 þ cells were recovered when both the CD34 þ and CD34 À cell fractions were Stem cell function of immunomagnetically separated CD34 þ cells T Kimura et al combined (Figures 1a and 3a) , while approximately 20% of the CD34 þ cells were lost during processing by either device. In contrast, the recovery of CFCs in the CD34 þ cell fraction was found to be very low, especially with the Isolex 50 system, because the colony-forming activity of CD34 þ cells selected by the Isolex 50 was markedly reduced (Tables 2 and 3 ). As shown in Figure 1b , the median recovery of CFCs from the CD34 þ cell fraction was 30.8% with the MiniMACS vs only 2.1% with the Isolex 50. In the case of the CD34 À cell fraction obtained with the MiniMACS, median CFC recovery was 5% vs 19% with the Isolex 50 (Figure 3b) . Overall, only 36% (median) or 21% (median) of total CFCs were recovered in both fractions by the MiniMACS and the Isolex 50, respectively. These results clearly showed that there were marked discrepancies between the two methods in the overall recovery of CD34 þ cells and total CFCs. In other words, a significant percentage of CD34 þ cells showed loss of colony-forming ability, despite being evaluated as viable by trypan blue dye exclusion. The extremely low recovery of total CFCs with the Isolex 50 seemed to be primarily due to the very low PE (median, 4.1%) of the selected CD34 þ cells (Tables 2 and 3 ). In our experience, the PE of sorted CD34 þ cells is usually in the range of 20-50%, as reported previously. 21, [23] [24] [25] [26] 33 Moreover, the CAFC activity of CD34 þ cells selected by the Isolex 50 was significantly reduced compared with that of CD34 þ cells selected by the MiniMACS (Figure 4 ) or the StemSep (Table 3) .
As presented in Table 3 , CD34 þ cells enriched by the StemSep showed significantly higher HPC activity than those selected by the Isolex 50, while cells selected by the MiniMACS showed almost comparable HPC activity with those selected by the StemSep. Taken together, these results indicate that HPC activity, which is usually possessed by CD34 þ cells, may be significantly impaired by the Isolex 50 separation procedure. In separate experiments, we confirmed that treatment with the releasing peptide for the Isolex 50 system caused a significant decrease in the CFC activity of MiniMACS-selected CD34 þ cells (data not shown). This suggests that the Isolex 50-releasing peptide may impair the functions of these progenitor cells.
In contrast to the loss of HPC activity, including CFCs and CAFCs, CD34 þ cells selected by the Isolex 50 system still effectively reconstituted human hematopoiesis in all 13 NOD/ SCID mice (Figure 5a and b) . The CD34 þ cells selected by the MiniMACS also reconstituted the BM of all 15 NOD/SCID mice. Furthermore, the percentage of human CD45 þ cells in the BM was significantly higher than in mice engrafted with cells from the Isolex 50 (Po0.05), being comparable to that in mice engrafted with cells enriched by the StemSep. These results suggested that the most primitive assayable human HSCs had greater resistance to the adverse effects of cell processing than the more differentiated HPCs, including CFCs and CAFCs. More importantly, SRC activity was retained after all of the separation procedures, since SRCs contribute to long-term lymphomyeloid reconstitution.
Recently, it was reported that the long-term lymphomyeloid repopulating stem cells in mice were CD34-low/negative (CD34 low/À ) cells. 34 In addition, human BM-and cord bloodderived CD34
À cells have shown long-term hematopoietic reconstituting activity in a human/sheep competitive engraft model 35 and in a SRC system using NOD/SCID mice. 30 Very recently, we identified a novel class of primitive human CD34 À SRCs that were only detected using intra-BM injection. 31 Therefore, it seems to be important for these CD34 À SRCs to be transplanted with CD34 Stem cell function of immunomagnetically separated CD34 þ cells T Kimura et al potential. Further precise studies using xenotransplantation systems are required to fully characterize immunomagnetically separated CD34 þ cells.
